|
|
|
Substance Name: Gilteritinib [USAN:INN]
RN: 1254053-43-4
UNII: 66D92MGC8M
InChIKey: GYQYAJJFPNQOOW-UHFFFAOYSA-N
Note
- An FLT3/AXL protein tyrosine kinase inhibitor.
NCI: An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival. (NCI Thesaurus)
Molecular Formula
- C29-H44-N8-O3
Molecular Weight
- 552.7196
Classification Code
- Treatment of Acute Myeloid Leukemia
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Gilteritinib [USAN:INN]
Synonyms
- 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-
- ASP 2215
- ASP2215
- Gilteritinib
- UNII-66D92MGC8M
Registry Numbers
CAS Registry Number
- 1254053-43-4
FDA UNII
- 66D92MGC8M
System Generated Number
- 1254053434